Patient-Specific Factors to Consider in CLL Treatment Management

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center discusses the patient-specific factors affecting treatment decisions in chronic lymphocytic leukemia (CLL). 


Because we’re really starting to use some of these small molecule inhibitors in practice, earlier or in combination with other agents, really thinking about the toxicity profile of these agents. If we’re using them in combination with IV therapy, this can certainly make it very complicated for the patient in terms of adherence, different alternating schedules, different billing. So really helping the patient navigate that process from an adherence, financial perspective can be very helpful. Thinking through the long-term effects of these therapies from an infection perspective as well. So I think we’re starting to see these agents really being used in combination which is exciting. But because they certainly do have a significant toxicity profile, there are a number of patient-specific factors to consider in terms of pill burden, in terms of cost, in terms of specific precautions to be aware of up front to make sure we consider the right drug in the right patient.

Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.